A Phase 3 interventional study of Dutogliptin and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Forest Laboratories. Terminated at 149 sites in United States. Open to participants aged 18 Years to 86 Years. Per ClinicalTrials.gov, last updated 2011-09-21.
Sponsored by Forest Laboratories · Phase 3, Interventional, and Treatment
This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM).
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's enrollment of 141 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Forest Laboratories is the lead sponsor of 165 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Dutogliptin
Drug: Sitagliptin
400 mg tablet, once daily
Also known as: PHX1149
100 mg capsule (each capsule contains two 50-mg tablets), once daily
Also known as: Januvia
To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG
Time frame: 52 weeks
To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.
Time frame: 52 weeks
Showing the first 100 of 149 sites.
This study is terminated, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Forest Laboratories